Previous close | 5.47 |
Open | 0.00 |
Bid | 5.34 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 169,244 |
Market cap | 5.418B |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | 34.39 |
EPS (TTM) | 0.16 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 03 Jun 2021 |
1y target est | N/A |
Europe's main stock indices were flat on Friday, but notched strong gains over the week that saw record highs from German and French shares, while investors also analysed a U.S. jobs report for clues on the global monetary policy outlook. Technology lost 1.6% after BE Semiconductor slumped 16.1% on a media report that Joint Electron Device Engineering Council lowered certain chip standards which might delay investments into hybrid bonding technology.
Shares of Spanish drugmaker Grifols rose more than 16% on Friday morning after it said auditor KPMG approved its 2023 results with an unqualified opinion, without modifying the profit and debt ratio previously reported. Grifols last week published its 2023 results, pending an audit, which analysts said contributed to the share price's tumbling along with doubts about its cash flow for 2024. Since early January, a report by short-seller fund Gotham City Research that questioned Grifols' accounting and debt ratio has cast doubts about the company's business and wiped off billions of euros in market value.
Grifols SA (NASDAQ:GRFS) shares are down on Wednesday following the publication of a new report by Gotham City Research questioning the company’s “transparency, integrity and ethical conduct.” Grifols had previously denied Gotham City’s accusations, as per its February SEC filing, saying it had already replied to all of the questions raised in the latter’s reports. Grifols claimed in its public February 20 response that the company had addressed all our questions, yet new information from the Ke